NCT03110978View on ClinicalTrials.gov

Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

June 26, 2017

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Lung Atypical Carcinoid TumorLung Neuroendocrine NeoplasmLung Non-Small Cell Squamous CarcinomaMinimally Invasive Lung AdenocarcinomaNeuroendocrine CarcinomaRecurrent Lung AdenocarcinomaRecurrent Lung Large Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage I Lung Cancer AJCC v8Stage IA1 Lung Cancer AJCC v8Stage IA2 Lung Cancer AJCC v8Stage IA3 Lung Cancer AJCC v8Stage IB Lung Cancer AJCC v8Stage IIA Lung Cancer AJCC v8
Interventions
BIOLOGICAL

Nivolumab

Given IV

RADIATION

Stereotactic Body Radiation Therapy

Undergo stereotactic body radiation therapy

Trial Locations (3)

77030

M D Anderson Cancer Center, Houston

77079

MD Anderson West Houston, Houston

77384

MD Anderson in The Woodlands, Conroe

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER